Neuland Laboratories Limited (NSE:NEULANDLAB)
22,216
-639 (-2.80%)
Aug 10, 2026, 3:30 PM IST
Neuland Laboratories Revenue
Neuland Laboratories had revenue of 6.42B INR in the quarter ending June 30, 2026, with 119.15% growth. This brings the company's revenue in the last twelve months to 23.72B, up 78.33% year-over-year. In the fiscal year ending March 31, 2026, Neuland Laboratories had annual revenue of 20.23B with 36.98% growth.
Revenue (ttm)
23.72B
Revenue Growth
+78.33%
P/S Ratio
12.01
Revenue / Employee
10.86M
Employees
2,183
Market Cap
284.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 20.23B | 5.46B | 36.98% |
| Mar 31, 2025 | 14.77B | -817.43M | -5.24% |
| Mar 31, 2024 | 15.59B | 3.67B | 30.81% |
| Mar 31, 2023 | 11.91B | 2.40B | 25.20% |
| Mar 31, 2022 | 9.52B | 147.07M | 1.57% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emcure Pharmaceuticals | 96.83B |
| Ipca Laboratories | 96.47B |
| Piramal Pharma | 92.05B |
| Alembic Pharmaceuticals | 77.84B |
| Gland Pharma | 64.31B |
| Ajanta Pharma | 57.76B |
| NATCO Pharma | 40.78B |
| Wockhardt | 34.62B |
Neuland Laboratories News
- 5 days ago - Gland Pharma, Neuland enter into long-term sterile API CDMO partnership - The Times of India
- 5 days ago - Neuland Laboratories Transcript: Q1 26/27 - Transcripts
- 5 days ago - Neuland Laboratories Quarterly report: Q1 2027 - Filings
- 5 days ago - Neuland Laboratories Slides: Q1 2027 - Filings
- 3 months ago - Neuland Laboratories announces Rs 34 per share dividend and appoints new director - Business Upturn
- 3 months ago - Neuland Laboratories Transcript: Q4 25/26 - Transcripts
- 3 months ago - Neuland Laboratories Quarterly report: Q4 2026 - Filings
- 3 months ago - Neuland Laboratories Slides: Q4 2026 - Filings